[Form 4] Tenon Medical, Inc. Insider Trading Activity

Q: What did Tenon Medical (TNON) report in this Form 4?

An award of 281,872 restricted stock units to CEO, President, and Director Steven Foster on October 13, 2025 .

Q: How do the RSUs convert for TNON?

Each RSU represents a contingent right to receive one share of common stock .

Q: What is the vesting schedule for the 281,872 RSUs at TNON?

50% vests on January 1, 2026 and 50% on July 31, 2026 .

Q: What price is associated with the RSU derivative security?

The filing lists a derivative security price of $0 .

Q: What ownership form is reported for these TNON RSUs?

The ownership form is reported as Direct .

Q: Who received the TNON RSU grant?

Steven Foster , the company’s CEO, President, and Director .

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tenon Medical (TNON)281,872 restricted stock units on October 13, 2025. Each RSU represents the right to receive one share of Tenon common stock. The filing states a derivative security price of $0.

The award vests in two equal tranches: 50% on January 1, 2026 and the remaining 50% on July 31, 2026. The ownership reported for these derivative securities is Direct.

Tenon Medical (TNON) ha comunicato un Modulo 4 per l'amministratore delegato, presidente e direttore Steven Foster che mostra una concessione di 281.872 unità di azioni ristrette il 13 ottobre 2025. Ogni RSU rappresenta il diritto a ricevere una azione ordinaria di Tenon. La dichiarazione indica un prezzo della sicurezza derivata di $0.
L'assegnazione vince in due tranche uguali: 50% il 1 gennaio 2026 e il rimanente 50% il 31 luglio 2026. La proprietà segnalata per tali strumenti derivati è Diretta.

Tenon Medical (TNON) divulgó un Formulario 4 para el CEO, Presidente y Director Steven Foster que muestra la concesión de 281,872 unidades de acciones restringidas el 13 de octubre de 2025. Cada RSU representa el derecho a recibir una acción ordinaria de Tenon. La declaración indica un precio de la seguridad derivada de $0.
El premio vence en dos tramos iguales: 50% el 1 de enero de 2026 y el restante 50% el 31 de julio de 2026. La titularidad reportada para estos valores derivados es Directa.

Tenon Medical (TNON)은 CEO, 사장 및 이사인 Steven Foster를 위한 Form 4를 공개했고, 281,872개의 제한 주식 단위(RSU)가 2025년 10월 13일에 부여되었음을 보여줍니다. 각 RSU는 Tenon 일반주 1주를 받을 권리를 나타냅니다. 제출서에는 파생증권 가격이 $0임이 명시되어 있습니다.
수여는 두 개의 동등한 구간으로 vest됩니다: 50%가 2026년 1월 1일에, 나머지 50%가 2026년 7월 31일에 vest됩니다. 이러한 파생증권에 대한 소유권은 Direct로 보고되었습니다.

Tenon Medical (TNON) a divulgué un Form 4 pour le PDG, Président et Directeur Steven Foster montrant l'octroi de 281 872 unités d'actions restreintes le 13 octobre 2025. Chaque RSU donne droit à recevoir une action ordinaire de Tenon. Le dépôt indique un prix de la sécurité dérivée de 0 $.
L'attribution est établie en deux tranches égales: 50% le 1er janvier 2026 et le reste 50% le 31 juillet 2026. La propriété déclarée pour ces dérivés est Directe.

Tenon Medical (TNON) hat ein Form 4 für den CEO, Präsidenten und Direktor Steven Foster offengelegt, das die Gewährung von 281.872 beschränkten Aktieneinheiten (RSU) am 13. Oktober 2025 zeigt. Jede RSU berechtigt zum Erhalt von einer Aktie der Tenon-Stammaktie. Der Einreichung zufolge beträgt der Preis der derivativen Sicherheit 0 $.
Die Zuteilung vest in zwei gleichen Tranchen: 50% am 1. Januar 2026 und die restlichen 50% am 31. Juli 2026. Das Eigentum, das für diese Derivate angegeben wird, ist Direct.

Tenon Medical (TNON) كشفت عن نموذج 4 للرئيس التنفيذي، والرئيس، والمدير ستيفن فوستر، يظهر منحًا قدره 281,872 وحدة أسهم مقيدة في 13 أكتوبر 2025. كل RSU يمثل الحق في الحصول على سهم عادي واحد من Tenon. يُشير التقديم إلى سعر أداة مشتقة قدره 0 دولار.
يستحق المنح على فترتين متساويتين: 50% في 1 يناير 2026 والباقي 50% في 31 يوليو 2026. الملكية المبلَّغ عنها لهذه الأوراق المشتقة هي مباشر.

Tenon Medical (TNON) 已披露适用于 CEO、总裁兼董事 Steven Foster 的 Form 4，显示在 2025 年 10 月 13 日授予 281,872 股限制性股票单位（RSU）。每个 RSU 代表获取 Tenon 普通股一股的权利。提交文件显示衍生证券价格为 0 美元。
该奖励分两期等额归属：50% 于 2026 年 1 月 1 日归属，其余 50% 于 2026 年 7 月 31 日归属。报告的这些衍生证券的所有权为直接。

Positive

None.

Negative

None.

10/15/2025 - 12:00 AM

SEC Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*
FOSTER STEVEN M

(Last) (First) (Middle)

104 COOPER COURT

(Street)
LOS GATOS CA 95032

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X Director 10% Owner

X Officer (give title below) Other (specify below)

CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Restricted Stock Units ⁽¹⁾ 10/13/2025 A 281,872 ⁽²⁾ ⁽²⁾ Common Stock 281,872 $0 281,872 D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

2. Fifty percent (50%) of the total number of restricted stock units shall vest and automatically convert into shares of common stock of the Issuer (on one-for-one basis) on January 1, 2026 and the remaining fifty percent (50%) shall vest and automatically convert into the shares of common stock of the Issuer (on one-for-one basis) on July 31, 2026.

/s/ Steven Foster 10/15/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Tenon Medical (TNON) report in this Form 4?

An award of 281,872 restricted stock units to CEO, President, and Director Steven Foster on October 13, 2025.

How do the RSUs convert for TNON?

Each RSU represents a contingent right to receive one share of common stock.

What is the vesting schedule for the 281,872 RSUs at TNON?

50% vests on January 1, 2026 and 50% on July 31, 2026.

What price is associated with the RSU derivative security?

The filing lists a derivative security price of $0.

What ownership form is reported for these TNON RSUs?

The ownership form is reported as Direct.

Who received the TNON RSU grant?

Steven Foster, the company’s CEO, President, and Director.

[Form 4] Tenon Medical, Inc. Insider Trading Activity

FAQ

What did Tenon Medical (TNON) report in this Form 4?

How do the RSUs convert for TNON?

What is the vesting schedule for the 281,872 RSUs at TNON?

What price is associated with the RSU derivative security?

What ownership form is reported for these TNON RSUs?

Who received the TNON RSU grant?

NASDAQ:TNON

TNON Rankings

TNON Latest News

TNON Latest SEC Filings

TNON Stock Data

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	10/13/2025		A		281,872		⁽²⁾	⁽²⁾	Common Stock	281,872	$0	281,872	D

	/s/ Steven Foster	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Trending News

[Form 4] Tenon Medical, Inc. Insider Trading Activity

FAQ

What did Tenon Medical (TNON) report in this Form 4?

How do the RSUs convert for TNON?

What is the vesting schedule for the 281,872 RSUs at TNON?

What price is associated with the RSU derivative security?

What ownership form is reported for these TNON RSUs?

Who received the TNON RSU grant?

NASDAQ:TNON

TNON Rankings

TNON Latest News

TNON Latest SEC Filings

TNON Stock Data